Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118361 | 1.00 | JAK3 (0.47) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL27366298 | 0.76 | JAK3 (0.50) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL20862642 | 0.67 | JAK3 (0.55) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL20862666 | 0.67 | JAK3 (0.55) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL4935278 | 0.66 | KDM4E (0.37) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL18967632 | 0.66 | KHK (0.71) | JAK3LRRK2 | |
| SCHEMBL4932197 | 0.66 | KDM4E (0.37) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL25668430 | 0.65 | JAK3 (0.53) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL14325245 | 0.64 | GRM4 (0.45) | JAK3GRM4LRRK2NPC1MAPT | |
| SCHEMBL20862485 | 0.64 | JAK3 (1.00) | JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023070101-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING DEVIMISTAT AND A FATTY ACID OXIDATION INHIBITOR, A TYROSINE KINASE INHIBITOR, A GLUTAMINASE INHIBITOR, AND/OR A GLYCOLYSIS INHIBITOR | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220054445-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | RAFAEL PHARMACEUTICALS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220040133-A1 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | RAFAEL PHARMACEUTICALS INC (US) | 2022-02-10 | — | — | US | disclosed |
| CN-113543778-A | Therapeutic methods and compositions for treating cancer using 6, 8-bis-benzylthio-octanoic acid and an autophagy inhibitor | 拉斐尔制药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113543779-A | Oral therapy with 6, 8-bis-benzylthio-octanoic acid | 拉斐尔制药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | PDK4, PDK2, PDK1 | JAK3 389/4885GRM4 1031/4885LRRK2 2546/4885 |
| US-20220054445-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | BECN1, ATG7, SQSTM1 | JAK3 3651/4885GRM4 4234/4885LRRK2 663/4885 |
| US-20220040133-A1 | ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | SLC10A6, SLC10A1, SLC10A2 | JAK3 1972/4885GRM4 2929/4885LRRK2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.